This is a news story, published by CNBC, that relates primarily to Novo Nordisk news.
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster weight loss drug wegovy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss pills news, weight loss injections news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
experimental weight loss drug pillCNBC
•77% Informative
Danish drugmaker Novo Nordisk CEO Lars Fruergaard Jørgensen says amycretin could eventually become a best-in-class treatment for obesity.
Patients on the pill lost around 13.1% of their weight after 12 weeks , Jørgen says.
The Danish company is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy .
VR Score
83
Informative language
85
Neutral language
88
Article tone
formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links